Welcome to Regulatory Rapporteur. This site uses cookies. Read our policy.
The Organisation for Professionals in Regulatory Affairs
By Mehryar Behizad2021-11-23T14:15:00
Source: Adobe Stock
Michelle Lotte started the session. She summarised considerations of the MDD/MDR transition against submission to the FDA.
Join now to get access to:
Become a member today!
Not sure yet? Read one of our free editorials to see what you’re missing out on!